Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/5/2025

GnRH Agonists in Patients with a History of Cervical Cancer

Introduction to GnRH Agonist Use

  • There is no guideline or evidence establishing GnRH agonists as contraindicated in patients with a history of cervical cancer, according to the Journal of Clinical Oncology and Annals of Oncology 1, 2, 3
  • The American Society of Clinical Oncology states that GnRH analogues are not an effective method for fertility preservation, and established methods like embryo or egg cryopreservation should be preferred 4, 5

Clinical Context and Indications

  • If GnRH agonists are being considered for legitimate therapeutic indications (such as endometriosis, uterine fibroids, or hormone receptor-positive breast cancer), a history of treated cervical cancer does not preclude their use 5
  • GnRH agonists should not be used as the sole or primary method for fertility preservation in any cancer patient, including those with cervical cancer history 4, 5
  • The NCCN and ESMO guidelines indicate insufficient evidence to support GnRH analogues for protecting ovarian function during chemotherapy 6, 4

Patient Evaluation and Monitoring

  • Evaluate cervical cancer status: Confirm the cancer is adequately treated and patient is in remission 2
  • Discuss risks and benefits: If GnRH agonist is indicated for non-fertility preservation purposes, proceed with standard monitoring 5
  • Monitor appropriately: Follow standard oncologic surveillance protocols for cervical cancer history 2
  • Complete ovarian suppression with GnRH analogues requires several weeks after initiation, which may be relevant for treatment timing 4, 5